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Lafora disease (LD) is a fatal, autosomal recessive, glycogen-
storage disorder that manifests as severe epilepsy. LD results
from mutations in the gene encoding either the glycogen phos-
phatase laforin or the E3 ubiquitin ligasemalin. Individualswith
LD develop cytoplasmic, aberrant glycogen inclusions in nearly
all tissues that more closely resemble plant starch than human
glycogen. This Minireview discusses the unique window into
glycogen metabolism that LD research offers. It also highlights
recent discoveries, including that glycogen contains covalently
bound phosphate and that neurons synthesize glycogen and
express both glycogen synthase and glycogen phosphorylase.
Lafora disease: History
In 1911, Gonzalo Rodriguez-Lafora, one of Ramon y Cajal’s
(often considered the father of modern neuroscience) last great
Spanish disciples, reported autopsy results from an 18-year-old
patient with stimulus-sensitive resting and -active “myoclonus
epilepsy with dementia” and described “amyloid bodies in the
protoplasm of the ganglion cells” (1, 2). Virchow originally
defined the term “amyloid” as any substance that stained in a
manner similar to starch (3). The deposits were later shown to
be glycogen-derived accumulations of water-insoluble, starch-
like polyglucosans and were named Lafora bodies (LBs)2 (4, 5).
Gabriel Schwarz named the disease Lafora disease (LD, OMIM
254780), established it as an autosomal recessive disease, and
was the first to demonstrate the EEG 4–6-Hz polyspike waves
in LD and to use muscle biopsies to diagnose patients (6).
LD is an invariably fatal epilepsy that equally affects both
sexes (7–9).Onset is in adolescence, in apparently healthy teen-
agers, with absence seizures and/or visual auras. Patients then
typically experience generalized tonic–clonic seizures and
insidious decline in cognitive function. LD at onset is difficult to
separate from the idiopathic generalized epilepsies. Myoclonic
seizures, staring spells, and generalized convulsions follow, and
all escalate over time. LD patients also develop highly frighten-
ing epileptic and nonepileptic visual hallucinations. Initial
response to antiepileptic drugs is lost within 3 years and a con-
stant myoclonus ensues. The young person develops severe
dementia, seizes with increased frequency, becomes bedridden,
and death comes in the form of a particularlymassive seizure or
aspiration pneumonitis (10–12).
Lafora disease: Molecular causes
LD research was revolutionized in 1995 when Serratosa et al.
(13) used linkage analysis and homozygosity mapping to locate
the first chromosome locus, 6q23-25, for Lafora disease. Posi-
tional cloning by the Minassian and Serratosa labs (14, 15)
resulted in the discovery of the Epilepsy, Progressive Myoclo-
nus 2A (EPM2A) gene encoding the phosphatase laforin.Muta-
tions in EPM2A account for 50% of LD cases; hence, a quest
for the second LD locus ensued. Scherer and co-workers
(16) identified Epilepsy, Progressive Myoclonus 2B (EPM2B/
NHLRC1) in 6p22 as the second LD locus encoding the protein
malin.
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Laforin is a 331-amino acid bimodular protein that contains
a carbohydrate-binding module followed by a dual-specificity
phosphatase domain (Fig. 1A). Multiple groups demonstrated
that laforin dephosphorylates glycogen and phosphorylated
glucans and proposed that loss of laforin results in hyperphos-
phorylated glycogen that disrupts glycogen branching or
debranching and leads to longer glucose chains that develop
into LBs (Fig. 1B) (17–21). This hypothesis was corroborated by
Roach and co-workers (19, 20, 22) using a laforin-deficient
mouse model that forms LBs and develops epilepsy showing
that laforin dephosphorylates glycogen both in vitro and in vivo.
Additionally, the recent X-ray crystal structure of laforin eluci-
dated how laforin binds and dephosphorylates glycogen (23).
Although laforin is a glycogen phosphatase, malin contains a
RING domain and six NHL repeats characteristic of a class of
E3 ubiquitin ligases (Fig. 1C) (24). Dixon and co-workers (25)
demonstrated that malin is an E3 ubiquitin ligase. Using cell
culture systems as well as purified proteins, multiple groups
reported that malin uses laforin as an adaptor protein or scaf-
fold to polyubiquitinate protein targeting to glycogen (PTG)
(26–30). PTG is a targeting subunit of protein phosphatase 1
(PP1) that dephosphorylates and activates glycogen synthase
(31). Thus, it was proposed that malin forms a complex with
laforin and regulates proteins involved in glycogen metabolism
through ubiquitin-dependent proteasomal degradation. Addi-
tional cell culture work also identified glycogen-debranching
enzyme and glycogen synthase as targets for malin ubiquitina-
tion (26, 28). However, the protein levels of these presumptive
malin targets were not up-regulated in tissue from malin
knockout (KO) mice with the exception of glycogen synthase
(32–34). Yet for glycogen synthase, the total activity is
unchanged in WT versus malin KO tissues, and the increased
protein corresponds to an inactive form that accumulates in
LBs. Collectively, the data demonstrate that malin does not tar-
get these proteins for proteasomal degradation, and the defin-
itive function of malin in glycogen metabolism is unresolved
(32). Nonetheless, malin is a ubiquitin ligase, and it likely mod-
ulates some aspect of glycogen metabolism.
After identification of the genes encoding laforin and malin,
essentially all the Lafora research groups embarked on the elu-
cidation of possible mechanisms to link protein function with
the disease. From this work, several results and conclusions
have become accepted: laforin is a glycogen phosphatase in
vivo; neurons express both glycogen synthase and glycogen
phosphorylase; neurons contain low levels of glycogen; neuro-
nal glycogen provides protection during oxygen deprivation;
and overaccumulation of neuronal glycogen leads to neuronal
loss, locomotion defects, and reduced life span. These results
also demonstrated that LD is a glycogen storage disease (GSD)
and that suppressing glycogen synthesis and LB formation is a
promising approach to attack Lafora disease.
Glycogen: Structure andmetabolism
This topic is discussed in detail in this Minireview series by
Prats et al. (99), so we only briefly describe glycogen structure
and metabolism. Glycogen is the major mammalian storage
carbohydrate and plays an important role in energy metabo-
lism. Glycogen is composed of glucose units joined by -1,4-
glycosidic linkages with branches occurring every 12–14 units
via -1,6-glycosidic branches (Fig. 2A). In mammals, the two
major deposits of glycogen are in the liver and skeletal muscle,
butmany organs, notably the brain, also synthesize the polysac-
charide. Glycogen is synthesized through the cooperative
action of three enzymes, namely glycogen synthase (GS), glyco-
genin, and glycogen-branching enzyme, using UDP-glucose
(UDP-Glc) as the glucose donor. A glycogenin dimer initiates
the glycogen polymer by autoglucosylation of a conserved tyro-
sine residue leading to an -1,4-linked chain of 8–12 glucose
units (35). This oligosaccharide remains attached to glycogenin
and forms a primer that is converted into a full-size glycogen
particle by the combined actions of glycogen synthase and
branching enzyme (35). The coordinated action of these
enzymes results in a properly branched glycogen molecule that
is soluble and can be readily degraded by glycogen phosphoryl-
ase (GP) and debranching enzyme. Branches within glycogen
are evenly distributed, resulting in a spherical-like structure
with exposed nonreducing chain ends. This unique organiza-
tion allows cells to store up to55,000 glucose units/molecule
in a water-soluble form that can be rapidly degraded when the
cell or the body requires energy. Additionally, glycogen con-
tains trace amounts of covalently attached phosphate, and
recent work has demonstrated the importance of these phos-
phate moieties in both Lafora body generation and LD (19,
20, 33).
Glycogen synthesis anddegradation arehighly regulatedpro-
cesses that contribute to glucose homeostasis. Several mecha-
nisms allow for control of GS activity, including, but not limited
to, phosphorylation, allosteric activation, and intracellular
localization. Regulated breakdown of glycogen is mediated by
a cytosolic pathway involving glycogen phosphorylase and
glycogen-debranching enzyme. Glycogen is also transported to
lysosomes where it is directly hydrolyzed to glucose by a lyso-
somal -glucosidase (35). Glycogen is degraded to combat
ischemia in the brain, to fuel muscle contraction, and to gener-
ate free glucose in the liver to oppose hypoglycemia. Onemight
then wonder whether the abnormal glycogen of LD disturbs
Figure 1. A, schematic of laforin. CBM, carbohydrate-binding module; DSP,
dual-specificity phosphatase. B, glycogen is a soluble branched glucose poly-
mer. The EPM2A gene encodes the glycogen phosphatase laforin, and EPM2B
encodes the E3 ubiquitin ligasemalin. Mutations in EPM2A or EPM2B result in
glycogen that is hyperphosphorylated (red circles) and has disrupted glucose
chain branching. This abnormal, less-soluble glycogen aggregates to form
the Lafora bodies that cause Lafora disease. C, schematic of malin. RING, E2
interacting domain; NHL, protein interaction domain.
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glucose homeostasis, as it does in some GSDs. An initial study
suggested this might be the case, but the most recent study
indicates no change in whole-body glucose metabolism in LD
mouse models (36, 37). Furthermore, there is no clinical evi-
dence for hypoglycemia in LD patients.
Glycogen: Phosphorylation and LBs
Glycogen, LBs, and plant starch are all composed of -1,4-
linked glucose residues with -1,6-glycosidic branches (Fig.
2A). A major difference is water solubility with glycogen being
water-soluble and both LBs and plant starch being water-insol-
uble (5, 38, 39). Elegant studies in the 1960s demonstrated that
there are two sizes of LBs (type I and type II) and proposed that
LBs aremore similar to plant starch than to human glycogen (4,
5). Starch is the major repository of glucose units in plants. It
comprises two polymers: amylose that is essentially a linear
polymer of -1,4-linked glucose residues and amylopectin that
contains -1,4-linked glucose residues with -1,6-glycosidic
branches. Starch is water-insoluble due to the longer 15–25
glucose unit chains within amylopectin and an uneven
branching pattern that together allow glucose chains to form
helices (Fig. 2B) (40). These helices exclude water so as to pack
in a semi-crystalline structure and render starch water-insolu-
ble (41). Reversible phosphorylation of starch has a clearly
defined function in transitory plant starchwhere plants utilize a
cycle of starch phosphorylation, degradation, and dephosphor-
ylation (42, 43). Plants synthesize transitory starch in their
leaves during the day and then release the energy cache at night.
However, the semi-crystalline lattice of glucose chain helices
prevents efficient amylase degradation of the starch granule.
Phosphorylation of glucose at the C6 and C3 hydroxyls by glu-
can water dikinase and phospho-glucan water dikinase, respec-
tively, sterically disrupts the helices and allows efficient degra-
dation of the outer glucose layer by amylases. The amylases can
release glucose down to the phosphate moiety but do not effi-
ciently release glucose units past the phosphate. The glucan
phosphatases starch excess 4 (SEX4) and like sex four 2 (LSF2)
remove the phosphate, thereby resetting the cycle so that the
next layer of helices can be phosphorylated and the cycle
repeated (41, 43–45). The amount of phosphate within starch
depends on the source, ranging from0.034 phosphate per thou-
sand glucose residues to 2.73 in potato tuber (Fig. 2C) (41, 46,
47). Additionally, starch phosphorylation is a dynamic process,
and the starch surface has higher amounts of phosphate during
the night versus the day.
Studies from the 1980s and 1990s demonstrated that glyco-
gen contains trace amounts of phosphate (48–50).Whelan and
co-workers (48) postulated that the glycogen phosphate con-
tentmay relate to the age of the glycogen granulewith increased
phosphate being ametabolicmarker to promote lysosomal deg-
radation of glycogen. As discussed above, glycogen is degraded
via the action ofGP and glycogen-debranching enzyme, but it is
also degraded via the lysosome in a process recently termed
“glycophagy” (51). Phosphate might be a marker to distinguish
these two pathways. Alternatively, a recent study (52) reported
that laforin and glycogen phosphate play a role in glycogen
remodeling following exhausting exercise. They showed that
phosphate content remained low in WT mice following exer-
cise-induced glycogen depletion even after glycogen levels and
branching were restored. However, re-establishment of the ini-
tial glycogen-branching pattern was delayed in laforin KO
mice.
Roach and co-workers (22, 54, 55) and Minassian and co-
workers (53) have demonstrated that LBs contain an increased
proportion of phosphatemonoester groups covalently attached
to hydroxyls at the C2-, C3-, andC6-positions, and they possess
longer glucose chains than glycogen (Fig. 2A). They also
showed that the physicochemical properties of overaccumu-
lated muscle glycogen were significantly altered in laforin KO
mice, the polysaccharide becoming lesswater-soluble andmore
aggregated, consistent with a greater tendency to precipitate in
LBs (19). Although LBs possess longer glucose chains, there is
no glycogen synthase hyperactivity nor branching enzyme defi-
ciency in LD that could directly explain the change in branching
or LB formation (56). An initial hypothesis was that phosphor-
ylation at the C6-position might physically block chain forma-
tion. More recent data demonstrate that the stoichiometry of
glycogen phosphate is low with only 1 phosphate per 300 glu-
coses to 1 phosphate per 3000 (Fig. 2C), depending on the
Figure 2. A, glucose is linked by -1,4- and -1,6-glycosidic bonds, and it is phosphorylated at the C2-, C3-, and C6-positions (red circles). B, glucose chains of
plant amylopectin and LBs are longer than glucose chains in glycogen and are proposed to formhelices. C, stoichiometry of covalently attached phosphate to
different glucans. D, concentration of glycogen in different cell types.
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source (22, 53, 54). Thus, no more than 1% of the potential
branch points are blocked. Even with the increased phosphor-
ylation in LD, the level of C6 phosphorylation is likely too low to
directly impact branch formation. Another hypothesis is that
phosphorylation may disrupt the complex hydrogen bonding
and other interactions that stabilize glucose chains within gly-
cogen, similar to what is seen in plants. This hypothesis may
account for the gross chemical differences between glycogen
and LBs, but the exact mechanism by which branching is
decreased is unresolved.
The mechanism responsible for the introduction of phos-
phate into glycogen remains an active area of study. There is no
biochemical or bioinformatic evidence for the existence of gly-
cogen dikinases akin to the enzymes that phosphorylate plant
starch. Roach and co-workers (54, 55) reported that glycogen
synthase can transfer the-phosphate ofUDP-glucose into gly-
cogen as a rare (1 in 10,000 catalytic cycles) side reaction.
They proposed the formation of a cyclic glucose phosphodi-
ester intermediate in the active site that could account for phos-
phate at the C2-position and possibly at the C3-position, but
they could not explain the phosphorylation at C6. Therefore,
other mechanisms must also be operative (57). Validating the
hypothesis of a cyclic glucose phosphodiester intermediate is
especially challenging, but a crystal structure of yeast glycogen
synthase with glucose-1,2-cyclic phosphate bound showed that
the catalytic site could accommodate the cyclic phosphate in a
manner consistent with the proposedmechanism (58). In addi-
tion, incubation of glycogen synthase with UDP-Glc results in
the generation of glucose-1,2-cyclic phosphate. Because of the
results with glycogen synthase, Roach (59) went so far as to
propose that the phosphate had no biological function and was
perhaps simply the result of aminor side reaction, inwhich case
laforin could be viewed as a repair or damage control enzymeby
keeping the phosphorylation level within tolerable limits.
Though excessive phosphate in glycogen may be detrimental,
whether the phosphate normally has a biological role is some-
what of a mystery.
Less controversial is the idea that laforin dephosphorylates
glycogen, and some studies have begun to address the site spec-
ificity. Analysis of glycogen from laforin and malin KO mice
indicated similar proportional increases in C6 and C2  C3
phosphate in glycogen, indicative of broad laforin specificity
(22). Kooi and co-workers (60) explicitly examined this issue in
vitro, showing that laforin can dephosphorylate both the C3-
and C6-position of glycogen, but preferentially dephosphory-
lates the C3 position. Some LD patient mutations in laforin
alter the C3/C6 specificity, suggesting that phosphorylation of
different positions may have differential effects on glycogen, as
is known to be the case with starch (60). Future studies are
necessary to define this additional dimension of glycogen
metabolism.
Glycogen in neurons
Glycogen functions as an energy reserve that is predomi-
nately found in the liver and skeletal muscle, but the brain is the
organ most susceptible to decreases in glucose availability (61,
62). In fact, the brain is partly protected from hypoglycemia via
elaborate blood glucose homeostatic mechanisms whereby the
liver supplies glucose, derived from glycogen or gluconeogene-
sis, to the bloodstream as dictated by nutritional status. Addi-
tionally, the brain possesses glycogen reserves thatwere initially
thought to simply be emergency energy stockpiles, but recent
data suggest that this glycogen participates in multiple aspects
of neural activity. However, themetabolism of brain glycogen is
a complex process that is incompletely understood, and oppos-
ing opinions exist regarding its function and themechanisms of
energy substrate utilization.Many of these differences arise due
to the difficulty of studying glycogen in the brain because of its
rapid degradation ex vivo during purification, its sensitivity to
stimuli via multiple signaling mechanisms, and the lack of tem-
poral-spatial resolution in vivo. These technical hurdles have
contributed to controversies regarding both the fate of glucose
once it enters the brain both in neurons and glia and differing
opinions regarding metabolic shuttling of glucose metabolites
between cells in the brain. Most notably among these contro-
versies is the astrocyte–neuron lactate shuttle hypothesis
(ANLSH). Multiple recent reviews capture these opinions and
controversies in great detail (62–66). Thus, we will not address
these issues, but rather highlight the unique insights obtained
regarding neuronal glycogen from studying LD.
Total brain glycogen ranges from 15 to 100 nmol of Glc/mg
of protein (Fig. 2D) with astrocytes containing substantial
amounts of glycogen (60–200 nmol ofGlc/mgprotein; Fig. 2D),
especially in areas with high synaptic density (67–70). During
the past 20 years, the perceived role of brain glycogen has
shifted from an emergency energy supply to a dynamic partic-
ipant in brain metabolism (62, 64). For example, (i) both mice
and young chickens lacking glycogen in the brain show an
impairment in long-term memory formation and in synaptic
plasticity (71, 72). (ii) Clearance of extracellular K ions
appears to be fueled by glucose 6-phosphate generated from
glycogen (73, 74). In the absence of K ion clearance, neuronal
hypersynchronization burst firing and seizures occur. (iii) The
metabolism of glutamate, the most important excitatory neu-
rotransmitter in the CNS, is linked with glycogen metabolism
(75, 76). These studies suggest that excess glutamate is shuttled
into glycogen, whereas the decreased glycogen breakdown
leads to glutamate deficiency. (iv) One of the most potent pro-
convulsant drugs, L-methionine-SR-sulfoximine, promotes for-
mation of masses of abnormally structured glycogen (62). Mice
that resist formation of these malstructured glycogen particles
resist the proconvulsant effect of the drug through unknown
mechanisms (62). Conversely, mice devoid of brain glycogen
show an increased susceptibility to kainate-induced epilepsy
(77). (v) In cases of common refractory epilepsy, mesial tempo-
ral lobe epilepsy, up to 50% of cases show abundant, sometimes
profuse, polyglucosan bodies, indistinguishable from LBs, in
surgically resected tissue (78, 79). These and other data are
establishing an as yet poorly understood link between glycogen
metabolism and epileptogenesis. The surprisingly severe epi-
lepsy of LD renders this disorder, and its further elucidation, an
entryway to understanding this poorly explored but possibly
critical facet of epilepsy and epilepsy intractability.
Although many cell types in LD patients develop LBs, neu-
rons are especially susceptible to energy perturbations; thus,
LBs trigger neuronal apoptosis, LD, and ultimately early death
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(38). The CNS is an interesting case in relation to glycogen
metabolism. In embryonic stages, glycogen appears both in glial
and neuronal cells, but in adults glycogen is almost exclusively
found in astrocytes (80). However, paradoxically, adult neurons
express glycogen phosphorylase (81, 82). Guinovart and co-
workers (28, 83) demonstrated that neurons also express glyco-
gen synthase and glycogen phosphorylase, thereby conferring
them the capacity to synthesize and degrade glycogen. They
also revealed that cultured neurons contain low levels of glyco-
gen (6 nmol of Glc/mg of protein) (Fig. 2D) (83). Furthermore,
glycogen metabolism protects both cultured primary neurons
and in vivo fly neurons during oxygen deprivation, thus dem-
onstrating a functional role for neuronal glycogen (83). These
discoveries were remarkable because until then it had been
widely accepted that neurons do not accumulate glycogen.
Although glycogen synthesis occurs in neurons, it must be
tightly controlled because overaccumulation (400 nmol of
Glc/mg of protein) induces neuronal apoptosis (28). Strikingly,
when primary neurons are forced to overaccumulate glycogen,
they produce a poorly branched glucose polymer reminiscent
of an LB that induces neuronal apoptosis (28). This finding was
confirmed in vivo by overexpressing an active form of GS in
neurons of mice and flies, independent of manipulating laforin
ormalin (84). Guinovart and co-workers (28, 83) demonstrated
that progressive glycogen accumulation inmouse andDrosoph-
ila neurons leads to neuronal loss, locomotion defects, and
reduced life span, supporting the hypothesis that aberrant gly-
cogen accumulation is the etiological cause of autophagy
impairment, neuronal apoptosis, and LD.
Cumulatively, these data contradict the widely held view that
neurons do not contain glycogen. Additionally, these results
settle the apparent paradox of how a cell type that was thought
to have no capacity to synthesize glycogen accumulates Lafora
bodies.
LDmousemodels establish diseasemechanisms and
therapeutic options
Several mouse models of LD have been generated (32–34,
85–88). Yamakawa and co-workers (86) generated the first
laforin LD mouse model and demonstrated that whole body,
laforin-deficientmice formLBs and aremore prone to epileptic
activity. Multiple laboratories independently generated malin-
deficient mouse models that recapitulate LD (Fig. 3A) (32–34).
The Minassian, Roach, DePaoli-Roach, Guinovart, and Sanz
laboratories have all generated KO LDmouse models as well as
double KOmodels. Glycogen content in the brains of laforin or
malin KO animals is more than double that ofWT animals (32,
34, 87–89). This increase was accompanied by progressive loss
of neuronal cells and the consequent neurophysiological alter-
ations, namely changes in the electrophysiological properties of
hippocampal synapses and an increased susceptibility to kain-
ate-induced epilepsy (34). Thus, each LD model to date repli-
cates LB formation, spontaneous myoclonus, and reduced
threshold for convulsions.
Despite the long-recognized accumulation of aberrant glyco-
gen in LD, there was still no direct evidence whether the accu-
mulation of glycogen is the cause of LD. The LDmouse models
and cell culture models exhibit perturbations in more than just
glycogen metabolism. Mice and cells lacking laforin and/
or malin display increased endoplasmic reticulum stress,
autophagy impairment, and reduced clearance of misfolded
toxic proteins through the ubiquitin proteasome system (85,
90–92). Each of these pathways was proposed as an alternative
underlying cause of LD instead of LBs. Some hypothesized that
laforin and malin directly regulate these cellular processes.
One hypothesis postulated that the loss of malin or laforin
results in an autophagy defect, and autophagy was proposed
as the primary cause of LD neurodegeneration. Under these
circumstances, the accumulation of LBs could be a mere
epiphenomenon.
However, several groups independently and definitively
demonstrated that LBs are the cause of LDmyoclonus epilepsy
and neuronal apoptosis using multiple mouse models as fol-
lows. 1) Laforin KO mice lacking Ptg exhibit reduced LB
accumulation, resolved neurodegeneration, and resolved
myoclonic epilepsy (Fig. 3B) (88). 2) The lack of Ptg in malin-
deficient mice nearly completely eliminates LBs and rescues
the neurodegeneration, myoclonus, seizure susceptibility,
and behavioral abnormality (87). 3) Malin-deficient mice
lacking glycogen synthase (Gys1) are devoid of LBs, exhibit
normal electrophysiological properties, show decreased sus-
ceptibility to kainate-induced epilepsy, and do not exhibit
increased neurodegeneration (89). 4) Malin-deficient mice
lacking one Gys1 allele, and thus showing reduced GS
expression, partially rescue the phenotype (89).
Results from these mouse models demonstrate that de-
creased or complete absence of the glycogen synthesis machin-
ery ablates LB formation, neurodegeneration, and epilepsy.
Additionally, it is important to highlight that malin-deficient
mice lackingGys1 also exhibit normal autophagy, strongly sug-
gesting that malin does not regulate autophagy but rather LBs
Figure 3. A, periodic acid-Schiff (PAS) staining of cerebellum and soleus sec-
tions from WT mice show few stainable structures. Conversely, Epm2b/
mice exhibit dramatic numbers of stainable polyglucosans, i.e. LBs. Arrows
indicate examples of areas rich in LBs. Data are modified from Ref. 32. B,
periodic acid-Schiff staining of Epm2a/ skeletal muscle reveals dramatic
accumulations of LBs.Mice lackingboth Epm2a and Ptgdisplayminimal to no
LBs. Data are modified from Ref. 89.
THEMATICMINIREVIEW: Lafora disease and neuronal glycogen
J. Biol. Chem. (2018) 293(19) 7117–7125 7121
trigger autophagy impairment (89). These results demonstrate
that other cellular perturbations are consequences of aberrant
glycogen accumulation, i.e. LBs, rather than being directly reg-
ulated by malin or laforin.
Thus, excessive glycogen accumulation appears to be
responsible for the observed defects in malin and laforin KO
mice, including their epilepsy and neurodegeneration. Also, the
finding that deletion of one Gys1 allele partially rescues the
pathological phenotype and wholly rescues the neurological
phenotype strongly suggests that partial inhibition of glycogen
synthase activity prevents disease progression. This hypothesis
is further strengthened by the finding that the absence of Ptg by
itself, which decreases glycogen accumulation by 50%, also
resolves the murine disease. Cumulatively, these groups have
shown in the LDmouse models that reducing glycogen synthe-
sis by 50–100% through knockouts of the glycogen synthase
gene or the glycogen synthase activator Ptg gene rescuemurine
LD. These findings suggest that glycogen accumulation is
responsible for the epilepsy and functional consequences seen
in the LD mouse models, defining LD as a glycogenosis. More
importantly, they demonstrate that down-regulation of glyco-
gen synthesis eliminates LBs and rescues LD.
An emerging link between glycogenmetabolism and
epilepsy
LD offers a unique window into both normal neuronal glyco-
gen metabolism and epileptic disease when this metabolism is
perturbed. Although much effort focuses on defining the basic
mechanisms of LD and translating this work into therapeutics,
it may reveal pathogenic mechanisms related to common epi-
lepsies. These insights may be particularly informative to the
most daunting aspect of epilepsy, namely the intractability that
afflicts over 30% of patients. The mechanisms by which LD
glycogenosis affects neurons and neuronal networks to gener-
ate an intractable seizure disorder are intriguing. There are sev-
eral lines of evidence that implicate abnormal glycogen in the
generation of seizures and epilepsy.
First, a recent study and accompanying review suggested that
epilepsy may be as much a disease of energy metabolism as of
neuronal discharge (93, 94). Sada et al. (94) demonstrated that
blocking lactate dehydrogenase (LDH), the metabolic enzyme
proposed by the ANLSH to provide astrocyte–neuron cross-
talk, ablated neuronal excitation both in vitro and in an epilepsy
animal model. Furthermore, they demonstrated that the anti-
seizure drug (ASD) stiripentol inhibits LDH (94). The authors
surmise the mechanism of action is to block lactate generated
from astrocytic glycogen from being shuttled to neurons and
being utilized as a key energy source when energy consumption
is increased, i.e. during seizures. A subsequent study by
Samokhina et al. (95) studying epileptogenesis showed neuro-
nal release of lactate rather than uptake. They concluded that
blocking LDH instead causes energy deprivation via pyruvate-
induced inhibition of glycolysis. These results are similar to
those of Hall et al. (96) reporting that inhibition of LDH did not
interferewithneuronalmetabolism,andlactateshuttlingisincon-
sistent with their data. Given these opposing conclusions, there
is clearlymorework to do in this arena. Regardless of themech-
anism, the physiologically relevant targets of other ASDs are
currently unknown, with many only modestly affecting ion
channels; thus, other ASDs could also target key metabolic
enzymes.
Other studies have demonstrated that normal glycogen is
needed to clear extracellular K, because the astrocytic Na/
K-ATPase uses ATP generated from glucose 6-phosphate
originating from glycogen breakdown and only from glycogen
breakdown (73–75). Nonclearance of extracellular K results
in neuronal hypersynchronization and burst firing, the critical
mechanism of seizure generation and propagation. Therefore,
normal glycogen is essential to controlling hyperexcitability
and seizures (62, 77). In addition, normal glycogen synthesis
and breakdown are critical to the homeostasis of glutamate, the
most important excitatory neurotransmitter in the brain (62).
Furthermore, mesial temporal lobe epilepsy is one of the most
common types of refractory epilepsy. In tissue from refractory
cases going to surgery, up to 50% of patients show abundant,
sometimes profuse, polyglucosan bodies, indistinguishable
from LBs, indicating an important yet poorly studied link
between the accumulation of an abnormal glycogen and refrac-
tory epilepsy (78, 79). Recent work has demonstrated that neu-
ronal death in LD could be influenced by secondary cellular
insults via impairment in proteostasis mechanisms (97, 98).
Although these data are convincing, there is clearly muchmore
work to elucidate links between proteostasis, aberrant glycogen
metabolism, and epilepsy.
Defining the basic mechanisms of LD and translating these
findings into therapeutic options may provide insight into the
cause of intractability in epilepsy and may lead to rational
approaches to new therapies.
Conclusions
The central theme of LD revolves around the overaccumula-
tion of aberrantly structured glycogen as follows: LBs largely
consist of aberrant glycogen resulting from mutations in two
critical enzymes; laforin binds and dephosphorylates glycogen;
and the E3 ubiquitin ligase malin ubiquitinates enzymes
involved in glycogenmetabolism. LD is thus one of the family of
glycogen storage diseases and offers a unique window into
neuronal glycogen metabolism and disease. Despite glycogen
metabolism being a mainstay in textbooks, work on LD has
yielded a number of novel advances in our understanding of
glycogen metabolism: 1) glycogen contains covalently bound
phosphate; 2) laforin binds and dephosphorylates glycogen; 3)
neurons express both glycogen synthase and glycogen phos-
phorylase; 4) neurons synthesize glycogen; and 5) aberrant gly-
cogen accumulation causes autophagy impairment.
The LD field has generated a number of in vitro biochemical
and structural techniques, in situ cell culture models, and in
vivo mouse models. The quest now begins to utilize these sys-
tems to translate the cellular, structural, biochemical, and phys-
iological insights into putative treatments. Although these
hypotheses are directly applicable to LD, future findings may
impact other epilepsies by targeting key cellular processes as a
basis for treatment. Additionally, these findings may assist in
resolving some of the controversies surrounding the relation-
ship and mechanisms of energy metabolism in neurons and
astrocytes.
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